IDKmonitor® Infliximab Drug Level ELISA (Health Canada)
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: Health Canada Licensed. Not for sale in the U.S.
Kit Manual: Download
The IDKmonitor® Infliximab Drug Level ELISA is an enzyme immunoassay intended for the quantitative determination of free therapeutic TNFα antibodies infliximab (e.g., REMICADE®, Remsima®, Inflectra®) in EDTA plasma and serum.
Health Canada Licensed. For Laboratory Professional Use Only.
Not for sale in the U.S. Please contact us to order or get a quote.
If you are in the U.S., you can purchase the RUO version of the Infliximab Drug Level ELISA.
Browse our other IDKmonitor® Infliximab ELISAs.
Test Principle of the IDKmonitor® Infliximab Drug Level ELISA
This ELISA is designed to determine the quantity of free infliximab (therapeutic antibody against TNFα) in EDTA plasma or serum samples.
In the first incubation step, the free infliximab from the sample is bound to the specific monoclonal anti-infliximab antibody coated on the plate. To remove all unbound substances, a washing step is carried out. In a further incubation step, a peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase. Finally, an acidic stop solution is added to terminate the reaction.
The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free infliximab in the sample. A dose-response curve of the absorbance unit (optical density, OD) vs. concentration is generated using the values obtained from the standard. The concentrations of free infliximab in the samples are determined directly from this curve.
|6.5 × 10 × 4.5 in